Minireviews
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jul 28, 2019; 25(28): 3753-3763
Published online Jul 28, 2019. doi: 10.3748/wjg.v25.i28.3753
Table 1 Demographic information, clinical manifestation, and laboratory tests of pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome
ReferenceWang et al[37]Zhuge et al[17]Song et al[38]Wang et al[26]
Numbern = 117n = 108n = 116n = 84
Sex (male/female)78/3966/4278/3845/39
Age (yr)63 (52.5-69)161 (55-69)156.92 ± 12.39252.97 ± 15.282
Clinical manifestation
Ascites99.1% (116/117)98% (50/51)100% (79/79)100% (83/83)
Hepatomegaly70% (82/117)92% (47/51)75.95% (60/79)65.1% (54/83)
Abdominal distention98.3% (115/117)99.1% (107/108)98.3% (113/115)
Jaundice39.8% (43/108)52.9% (54/102)57.8% (48/83)
Right upper quadrant pain19.7% (23/117)36.4% (40/110)
Edema39.3% (46/117)39.5% (43/109)37.3% (31/83)
Weight gain18% (21/117)15.5% (16/103)
Splenomegaly34.2% (40/117)27% (14/51)25.35% (18/71)[39]
Gastroesophageal varices18.31%(13/71)[39]36.8%(7/19)
Laboratory tests
VariableMedian (25th-75th percentiles)Median (25th-75th percentiles)mean ± SDmean ± SD
ALT (U/L)49 (25.0-152.5)52.6 (26.8-125)134.50 ± 154.89216.83 ± 235.78
AST (U/L)75 (39.0-158.5)69.6 (42.4-115)146.31 ± 156.30221.15 ± 221.70
ALP (U/L)122 (86.8-191.3)130 (105-178)170 ± 106.89183.48 ± 59.96
γ-GT (U/L)100.7 (61.8-164.8)120 (72.4-170)160.52 ± 114.56155.70 ± 99.45
TB (μmol/L)33.3 (19.7-47.0)39.7 (28.3-62.4)65.07 ± 78.8352.96 ± 45.95
ALB (g/L)30.6 (27.7-33.6)32.1 (29.8-34.7)30.71 ± 5.5032.02 ± 4.51
PT (sec)14.8 (12.7-17.0)15.1 (14.2-16.7)17.43 ± 2.6418.08 ± 4.12
WBC (109/L)6.1 (5.0-8.7)6.1 (4.8-7.3)6.90 ± 2.81
RBC (1012/L)4.4 (3.9-4.9)5 ± 4.33
PLT (109/L)113 (78-153)95 (74-134)114.06 ± 63.48